Antlia Bioscience, Inc.

ENCINITAS, CA · Founded 2020 · CIK 0001829522 · Biotech · Private

Long-acting therapeutic formulations for cardiometabolic diseases

antliabio.com →
Grants
$1000K
1 award
Sector median: 1
Raised
$6.9M
3 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$207,000
Private capital raisedForm D · SEC$680,000
Federal grantDepartment of Health and Human Services · Phase II · A novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), to treat resistant hypertension$999,998
Private capital raisedForm D · SEC$6,000,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1887Protocol 46 Inc.—$410K
1888RETROVIROX, INC.——
1889Cotinga Pharmaceuticals Inc.—$3.0M
1890Antlia Bioscience, Inc.—$6.9M
1891PLEOPHARMA, INC.—$17M
1892D2G ONCOLOGY, INC.—$6.6M
1893OCATA THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Ben AuspitzDirector
  • Carlos EcheverriaDirector
  • Brian JohnsonDirector · Executive Officer
  • Ankit MahadeviaDirector · Executive Officer
  • Nihal SinhaDirector
  • Martin TaylorDirector

Patents

USPTO · 0 granted of 6
  • Modified B-type Natriuretic Peptideapplication
  • Modified B-type Natriuretic Peptideapplication
  • Modified Urocortin 3application
  • Modified B-type Natriuretic Peptideapplication
  • Modified B-type Natriuretic Peptideapplication
  • Modified B-type Natriuretic Peptideapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.